Stock Taper 
IPHA
$2.22
▼ DOWN 0.45% (-0.01)
KEY STATISTICS
Market Cap$208.47 M
52w High$2.71
52w Low$1.17
Dividend Yield—
Frequency—
P/E-3.49
Volume11.43K
Shares Out.93.90M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Jonathan E. Dickinson
ABOUT
SECTOR
Healthcare
WENT PUBLIC
October 17, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
163
PRICE TARGET
Target High$9.00
Target Low$4.00
Target Median$7.00
Target Consensus$6.67
UPCOMING EARNINGS
DateSep 17, 2026
DayThursday
Rev. Est.$5.81M
SEP
17
THU
PRICE
$2.22 ▼ DOWN 0.45% (−$0.01)About Innate Pharma S.A.
https://www.innate-pharma.com ↗Innate Pharma S.A. is a French biotech developing therapeutic antibodies for oncology and inflammatory diseases, with multiple products in clinical trials and collaborations with major pharma companies.
INDUSTRY
Biotechnology
A PRODUCT INNATE PHARMA S.A. IS KNOWN FOR
Lacutamab
Lacutamab, a first-in-class antibody in late-stage development for CTCL, has FDA Breakthrough Therapy Designation for Sézary syndrome and is preparing for Phase 3 trials, representing Innate Pharma’s leading proprietary candidate.
INSTITUTIONAL OWNERSHIP
SHARES OWNED
0.33%
HOLDERS
17
TOP 12 OF 17 · RANKED BY POSITION SIZE
Jane Street Group, LLC
Lion Point Capital, LP
Morgan Stanley
Old Mission Capital LLC
Millennium Management LLC
Citadel Advisors LLC
Rhumbline Advisers
Ubs Group AG
Gamma Investing LLC
Barclays Plc
Optiver Holding B.V.
Principal Securities, Inc.
RATINGS SNAPSHOT
Overall rating: C
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 2
MARKET PERFORM 1
3 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 NVCT | $23.73 | COMPARE |
 CGEN | $2.60 | COMPARE |
 CRBP | $10.91 | COMPARE |
 MOLN | $4.50 | COMPARE |
 MIST | $1.16 | COMPARE |
 CRDF | $0.94 | COMPARE |
 RANI | $0.84 | COMPARE |
 ELTX | $2.84 | COMPARE |